|
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg (USRLD: Solodyn Tablets, 55 mg, 65 mg, and 115 mg).
Minocycline Hydrochloride Extended-Release is used to treat moderate to severe acne in people 12 years and older.
Minocycline belongs to a class of drugs known as tetracycline antibiotics. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).
Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg had annual sales of USD 0.7 mn in the United States (IQVIA MAT April 2023).
|